NeoGenomics (NASDAQ: NEO)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-05 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.230 | -0.200 | 0.0300 | ||||
REV | 116.680M | 117.169M | 489.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of NeoGenomics (NASDAQ: NEO) through any online brokerage.
Other companies in NeoGenomics’s space includes: Medpace Hldgs (NASDAQ:MEDP), 10x Genomics (NASDAQ:TXG), Codexis (NASDAQ:CDXS), Syneos Health (NASDAQ:SYNH) and Sotera Health (NASDAQ:SHC).
The latest price target for NeoGenomics (NASDAQ: NEO) was reported by Piper Sandler on Friday, June 3, 2022. The analyst firm set a price target for 13.00 expecting NEO to rise to within 12 months (a possible 47.56% upside). 21 analyst firms have reported ratings in the last year.
The stock price for NeoGenomics (NASDAQ: NEO) is $8.81 last updated July 6, 2022, 8:00 PM UTC.
There are no upcoming dividends for NeoGenomics.
NeoGenomics’s Q2 earnings are confirmed for Friday, August 5, 2022.
There is no upcoming split for NeoGenomics.
NeoGenomics is in the Health Care sector and Life Sciences Tools & Services industry. They are listed on the NASDAQ.